Company Overview and News

to your dashboard

Headline News

ROTY Edition 1 Volume 68: An Exciting New Position And Other Updates

2018-01-08 seekingalpha
The JPMorgan Healthcare Conference is a significant event that readers interested in the sector should pay close attention to. (66-3)

Erytech Pharma: Buy The Dip

2018-01-04 seekingalpha
I revisit the bullish thesis below and remind readers of two upside driveres, ALL and pancreatic cancer. (23-3)

Recent IPO Erytech Pharma A Buy On Upcoming AML Data And Pipeline Progression

2017-12-02 seekingalpha
Its unique technology platform ERYCAPS has allowed it to develop a promising pipeline of candidates developed by encapsulating therapeutic drug substances inside red blood cells. (44-1)

EYRYY / Erytech Pharma - Stock Institutional Ownership and Shareholders -

Erytech Pharma (OTC:EYRYY) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 4,898,337 shares. Largest shareholders include Baker Brothers Advisors LP. (0-6)

U.S. IPO Weekly Recap: 10 Companies Go Public In The Busiest Week Of 2017

2017-11-14 seekingalpha
Ten companies raised a combined $1.6 billion in the most active week of the 2017 IPO market. Texas community bank CBTX took the top spot with a 10% pop, which is still below the long-term historical average of 13%. The week featured three regional banks, three biotechs, three fast-growing Chinese companies and a communications platform pivoting to growth. First-day pops for IPOs this week averaged just 3. (36-3)

IFR Americas ECM Pipeline

2017-11-09 reuters
Nov 8, 2017 - PRICED: Apellis Pharmaceuticals (US, biotech) – $150m IPO. 10.71m shares (100% prim) at$14 versus marketing at $13-$15. CITI, JPM. Cadence Bancorp (US, commercial bank) – $209m FO. 9.5m shares (100% sec) at $22.00 versus $23.00 last sale and $25.46 launch. GS, JPM. Sogou (Cayman Islands/China, internet search) – $585m IPO. 45m ADSs (100% prim) at $13.00 versus marketing at $11-$13. JPM, CS, GS, CICC, CREN. (33-0)

IPO Market Hot This Week: ETFs to Tap

2017-11-08 zacks
The U.S. IPO market is sizzling this week with 11 deals that will collectively raise more than $2 billion. This will mark the busiest week of this year. In particular, the Chinese companies have been at the forefront with the second-largest mobile search engine Sogou (SOGO) expected to go public on Nov 9. The company plans to raise $540 million at a market capitalization of $4.8 billion (read: What Lies Ahead for China Tech ETFs?).

Term Sheet -- Tuesday, November 7

2017-11-07 fortune
Yesterday, we noted that Valeant Pharmaceuticals is giving Addyi, the female libido drug dubbed ‘the female Viagra,’ back to its former owners. This is quite a big deal as Valeant bought Sprout Pharmaceuticals, the company behind the drug for a whopping $1 billion just over two years ago. (38-0)

U.S. IPO Week Ahead: Cybersecurity Unicorn ForeScout Technologies Headlines 6-IPO, 6-Sector Week

2017-10-21 seekingalpha
The steady flow of IPOs in the 4Q is set to continue with six companies in six different sectors scheduled to raise a combined $2.1 billion in the week ahead. The diverse collection includes unicorn ForeScout Technologies (Private:SCOUT), an enterprise security software provider that hopes to follow the success of the most recent unicorn to IPO, MongoDB (Pending:MDB), which priced last week and popped 34% on its first day. (49-0)

Erytech, Queen's Partner to Develop Red Blood Cell-Encapsulated Enzyme Therapy

2017-07-12 genengnews
Erytech Pharma established a research collaboration with Queen’s University in Canada to support continued preclinical development of its eryminase candidate for treating the rare metabolic disorder arginase-1 deficiency. Eryminase comprises the enzyme arginine deiminase encapsulated in red blood cells using Erytech’s proprietary Erycaps platform technology.

Invetech Release: Company Announces Agreement With ERYtech Pharma To Develop Scalable Automated Manufacturing System

2017-01-18 devicespace
SAN DIEGO, Jan. 18, 2017 /PRNewswire/ -- Invetech, the leading developer of cGMP manufacturing solutions for cell and advanced therapies, has announced a collaboration agreement with Erytech Pharma, the French biopharmaceutical company developing "tumor starvation" treatments for acute leukemia and other oncology indications with unmet medical needs. Under the agreement, Invetech will develop systems to enable the commercial-scale manufacture of products based on Erytech's proprietary ERYCAPS technology platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells and is designed to more effectively deliver therapeutics with reduced side effects.

What Makes NantHealth (NH) a Strong Sell?

2017-01-13 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

Invitae (NVTA) Catches Eye: Stock Adds 5.9% in Session

2017-01-05 zacks
Invitae Corporation (NVTA - Free Report) was a big mover last session, as its shares rose almost 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $6.87 to $8.75 cents in the past one-month time frame.

Looking for a Growth Stock? Why It is Time to Focus on Medidata Solutions (MDSO)

2016-11-18 zacks
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is Medidata Solutions, Inc.

Pfizer and NCI Ink Research Deal Targeting Multiple Cancers

2016-11-15 zacks
Pfizer Inc. (PFE - Free Report) announced that it has struck a research and development agreement with the National Cancer Institute (NCI) to study three immunotherapy agents targeting multiple cancers.